Yabao Pharmaceutical Group is an API manufacturer based in China. It holds 7 active US drug master files across a filed portfolio of 7 molecules. Its GMP standing is certified by US FDA. Its most recent recorded inspection, by US FDA, closed on 24 January 2025 as NAI.
NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.
| Site | FDA FEI |
|---|---|
| China, China | 3007426459 |
| Molecule | Regulators | Docs |
|---|---|---|
| Dabigatran Etexilate | US FDA | 1 |
| Dimethyl Fumarate | US FDA | 1 |
| Gefitinib | US FDA | 1 |
| Iron Sucrose | US FDA | 1 |
| Promestriene | US FDA | 1 |
| Sorafenib | US FDA | 1 |
| Tofacitinib | US FDA | 1 |
Also appears on these molecule pages
| Regulator | Filings | GMP certificates |
|---|---|---|
| US FDA | None | 1 |
Choose your molecules and target markets. Yabao Pharmaceutical Group comes back tiered against every other supplier able to file there.
Start for free